Investigational Drug Information for Dengue vaccine
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Dengue vaccine?
Dengue vaccine is an investigational drug.
There have been 15 clinical trials for Dengue vaccine.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 7th 2016.
The most common disease conditions in clinical trials are Dengue, COVID-19, and Severe Acute Respiratory Syndrome. The leading clinical trial sponsors are Takeda, Kafrelsheikh University, and Singapore General Hospital.
There are nine US patents protecting this investigational drug and one hundred and thirty-three international patents.
Summary for Dengue vaccine
| US Patents | 9 |
| International Patents | 133 |
| US Patent Applications | 0 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2016-09-07) |
| Vendors | 0 |
Recent Clinical Trials for Dengue vaccine
| Title | Sponsor | Phase |
|---|---|---|
| Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| The Immunostimulatory Effects of Gentamicin | Singapore General Hospital | Phase 2 |
| Investigating the Role of 13cis Retinoic Acid in the Treatment of COVID-19 and Enhancement of Its Spike Protein Based Vaccine Efficacy and Safety. | Kafrelsheikh University | Phase 1/Phase 2 |
Clinical Trial Summary for Dengue vaccine
Top disease conditions for Dengue vaccine
Top clinical trial sponsors for Dengue vaccine
US Patents for Dengue vaccine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Dengue vaccine | See Plans and Pricing | Process for preparing an attenuated tetravalent dengue vaccine | Fundacao Butantan (Sao Paulo, BR) | See Plans and Pricing |
| Dengue vaccine | See Plans and Pricing | Process for preparing an attenuated tetravalent dengue vaccine | Fundacao Butantan (Sao Paulo, BR) | See Plans and Pricing |
| Dengue vaccine | See Plans and Pricing | Tetravalent dengue vaccine | INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY (New Delhi, IN) | See Plans and Pricing |
| Dengue vaccine | See Plans and Pricing | Concomitant dengue and yellow fever vaccination | SANOFI PASTEUR (Lyons, FR) | See Plans and Pricing |
| Dengue vaccine | See Plans and Pricing | Substituted indoline derivatives as dengue viral replication inhibitors | Janssen Pharmaceuticals, Inc. (Titusville, NJ) Katholieke Universiteit Leuven (Leuven, BE) | See Plans and Pricing |
| Dengue vaccine | See Plans and Pricing | Inactivated dengue virus vaccine with aluminium-free adjuvant | GlaxoSmithKline Biologicals SA (Rixensart, BE) | See Plans and Pricing |
| Dengue vaccine | See Plans and Pricing | Compositions and methods for rapid immunization against dengue virus | Takeda Vaccines, Inc. (Deerfield, IL) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Dengue vaccine
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Dengue vaccine | Argentina | AR105966 | 2035-09-08 | See Plans and Pricing |
| Dengue vaccine | Australia | AU2016318349 | 2035-09-08 | See Plans and Pricing |
| Dengue vaccine | Brazil | BR102015030332 | 2035-09-08 | See Plans and Pricing |
| Dengue vaccine | Chile | CL2018000609 | 2035-09-08 | See Plans and Pricing |
| Dengue vaccine | China | CN108289945 | 2035-09-08 | See Plans and Pricing |
| Dengue vaccine | Colombia | CO2018003451 | 2035-09-08 | See Plans and Pricing |
| Dengue vaccine | Costa Rica | CR20180202 | 2035-09-08 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
